Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022. In the quarter to June 2026, revenue grew 4,922.2%, EPS fell 28.6% and free cash flow fell 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PLSE
Pulse Biosciences, Inc (PLSE) EV/Sales
As of 16 October 2026, Pulse Biosciences, Inc (PLSE) trades at a EV/Sales of 2,555×. Over the past ten years it has ranged from 0.0× (June 2022) to 3,193× (September 2026); the current reading is higher than 98% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,502× | 2,264.51% |
| FY2022 | 63.5× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1,589× | (19.54%) |
| Mar 2026 | 1,975× | 31.47% |
| Dec 2025 | 1,502× | 1.51% |
| Sep 2025 | 1,480× | 2,229.44% |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVST Envista Holdings Corporation compare | 1.4× |
| ICUI ICU Medical, Inc. compare | 2.3× |
| WRBY Warby Parker Inc. compare | 2.9× |
| MMSI Merit Medical Systems, Inc. compare | 3.6× |
| TFX Teleflex Incorporated compare | 3.6× |
| STVN Stevanato Group S.p.A. compare | 3.9× |
| ATRC AtriCure, Inc. compare | 4.7× |
| LMAT LeMaitre Vascular, Inc. compare | 6.3× |
| PLSE Pulse Biosciences, Inc | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)